REGN FY 2020 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8.5B+29.6% YoY

Gross Profit

$7.1B84.0% margin

Operating Income

$3.6B42.1% margin

Net Income

$3.5B41.3% margin

EPS (Diluted)

$30.52

Cash Flow

Operating Cash Flow

$2.6B

Free Cash Flow

$2.0B

Stock-Based Comp.

$432M

Balance Sheet

Total Assets

$17.2B

Total Liabilities

$6.1B

Stockholders' Equity

$11.0B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8.5B	$6.6B	+29.6%
Gross Profit	$7.1B	$5.6B	+27.9%
Operating Income	$3.6B	$2.2B	+61.9%
Net Income	$3.5B	$2.1B	+66.0%